" class="no-js "lang="en-US"> Sobi - Medtech Alert
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
Sobi | Pharmtech Focus

Sobi

About Sobi

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Today, we employ approximately 1,500 people across Europe, North America, Middle East and Asia. In 2020, our revenue amounted to SEK 15.3 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.

Related Story

Diseases

 ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma | PTF

ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® for the Treatment of Lymphoma

December 21 2022

ADC Therapeutics SA and Swedish Orphan Biovitrum AB (Sobi) has announced the European Commission (EC) […]

Appointments

 Sobi Continues the R&D Transformation - Anders Ullman Appointed New Head of R&D | Pharmtech Focus

Sobi Continues the R&D Transformation - Anders Ullman Appointed New Head of R&D

December 13 2021

Anders Ullman, M.D., Ph.D., currently a member of the Board of Directors of Sobi, will […]